Insulet Corporation announced the appointment of Flavia Pease as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Pease will succeed Ana Maria Chadwick, who will transition to a Senior Advisor role to ensure a smooth transition. Ms. Pease has served on Insulet’s Board of Directors since January 2024 and will resign from the Board upon assuming her new role.
Ms. Pease brings extensive global healthcare and medical technology industry experience, having most recently served as Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories. Her prior experience includes over 20 years at Johnson & Johnson, where she held leadership roles in Medical Devices and Pharmaceutical segments.
Insulet expects to exceed its previously issued third-quarter 2025 total revenue growth guidance, driven by strong new customer starts in both U.S. and international markets. The company plans to provide further details on its third-quarter results and an update to its full-year outlook during its earnings call scheduled for November 6, 2025.
The appointment of a new CFO with deep financial and MedTech expertise, particularly from a large global organization, is a positive strategic move for Insulet. Ms. Pease's prior board experience with Insulet ensures a strong understanding of the company's strategy. The simultaneous announcement of exceeding Q3 revenue guidance further reinforces confidence in the company's operational performance and growth trajectory.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.